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I. INTRODUCTION
If you have ever filled a drug prescription at any pharmacy in the
United States, you have heard the words, “so, would you like brand
name or generic?” Originator drugs (brand name drugs), those
chemically-synthesized and biotechnology derived are the original
drugs constructed in laboratories.1 These drugs are put through
various clinical tests,2 and the originator company relies on various
forms of intellectual property rights and patents in order to justify the
initial investment required to bring the drug to market in the U.S.3
Typically, originator patents last for several years, thus guaranteeing
that the originator company will be the only legal distributor of the
drug. Almost all originator drugs are more expensive than their
generic counterparts.4 Generic drugs are “duplicative copies of

* Michael Vincent Ruocco is a second year student at Pepperdine University
School of Law. Michael graduated from the University of San Francisco with a
Bachelor of Arts in Politics. He would like to thank Alex Baumann for her help
and guidance during the writing process. He would also like to thank his girlfriend
Emily Rose Casey for her loving support.
1

The Pharmaceutical Industry in the United States, SELECT USA,
http://selectusa.commerce.gov/industry-snapshots/pharmaceutical-industry-unitedstates (last visited May 21, 2013) [hereinafter “Select USA: Pharm Industry”].
2
Id. Originator drugs are tested first on animals, and then humans, in what are
referred to as clinical tests. Id.
3
Id. The major obstacle facing drug manufacturers, consumers, and insurance
companies nationwide is the cost associated with bringing a pharmaceutical drug to
market in the United States. Pharmaceutical Research and Manufacturers of
America (PhRMA) “represents the country’s leading pharmaceutical research and
biotechnology companies, which are devoted to inventing medicines that allow
patients to live longer, healthier, and more productive lives.” About PhRMA,
PHRMA, http://www.phrma.org/about/about-phrma (last visited Mar. 8, 2013).
According to PhRMA, “the average cost to develop one new approved drug–
including the cost of failures–[is $1,200,000,000.]”
Chart Pack:
Biopharmaceuticals
in Perspective,
PHRMA (2012),
available
at
http://www.phrma.org/sites/default/files/pdf/phrma_chart_pack.pdf.
4
Select USA: Pharm Industry, supra note 1. For example, filling my
prescription for Adderall is a perfect example of how prices can drastically vary
between brand name and generic brand versions of a drug. Adderall is the brand
name version of a psychostimulant medication that is used to help treat attention
deficit hyperactivity disorder (ADHD). The medication contains a combination of
four different amphetamine salts: racemic amphetamine aspartate monohydrate,
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chemically-synthesized drugs that contain the same active ingredient,
are identical in strength, dosage, form and route of administration,”
and can only be marketed once the originator’s patent expires.5
Generic drugs are attractive to most consumers because they are
typically sold at substantially lower prices than the originator drugs.6
For a middle class family paying for things such as tuition, gas bills,
grocery bills, and various other expenses, it is helpful in managing
the family’s budget to have the choice of purchasing generic drugs
that have the exact same ingredients and chemical effects as the
brand name version.
Many families are unable to purchase generic versions of certain
brand name drugs because the brand name manufacturers prevent
generic versions of the drug from coming to market. They do this for
one reason, and one reason only: PROFIT.7 The United States of

racemic
amphetamine
sulfate,
dextroamphetamine
saccharide,
and
dextroamphetamine sulfate. When I go to Rite Aid to fill my prescription for thirty
capsules of Adderall, I have the choice between the brand name (Adderall) and its
generic form. Adderall (brand name) comes in a time-release form (a technology
used in drug capsules that helps dissolve the prescription drug into the blood stream
over a certain period of time), while the generic form of Adderall comes in an
“instant release” (instant release means the capsule or tablet is released into the
blood stream immediately). On the one hand, if I elect to have my prescription for
thirty capsules filled with brand name Adderall without first meeting my $5,000
deductible with Anthem Blue Cross, the total cost to fill my prescription is $125.
Yet, if the pharmacist fills the prescription with the generic form of Adderall, and I
have not yet met my deductible, the total cost is only $15. Therefore, I always
choose the generic brand.
5
Select USA: Pharm Industry, supra note 1. The “route of administration”
typically refers to whether a drug is administered with time release or instant
release technology. See supra note 4.
6
Many consumers have some type of health insurance that requires them to
pay a certain amount of money for their doctor visits, prescriptions, etc. before the
insurance company will help cover their medical costs. It is much more cost
effective for the average consumer to purchase the generic form of a drug, as
typically the generic version is much less expensive than the brand name version,
especially if the insurance is not helping them pay for it. See supra note 4.
7
Take for example the drug Viagra, which is manufactured by Pfizer and is a
brand name drug used to treat erectile dysfunction in men. Viagra was approved
by the FDA in 1998 and sales of the drug surpassed 1,000,000,000 its first year.
See David L. Shedlarz, Pfizer Inc. Financial Report (1998). According to Phrma, it
should have cost Pfizer $1,200,000,000 to bring the drug to market in the U.S. See
supra note 3 explaining how much it costs to introduce a pharmaceutical drug in
the U.S. Pfizer made almost all of the money that it cost them to research and
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America is currently home to the world’s largest market for
pharmaceuticals and is the forerunner in biopharmaceutical research.8
It is estimated that U.S. pharmaceutical companies conduct eighty
percent of the world’s research on biopharmaceutical drugs and own
most of the intellectual property rights to the new drugs that are
developed.9 “Americans . . . spend a staggering $200 billion a year
on prescription drugs, and that figure is growing at a rate of about 12
percent [per] year (down from a high of 18 percent in 1999).” 10 The
U.S. pharmaceutical market has a favorable patent and regulatory
environment, which allows pharmaceutical companies to freely price
their drugs at whatever price level the market can sustain.11 The
success of a drug is largely based on its safety, quality, and
efficacy.12 Drug manufacturers are constantly competing with one
another to produce the best product possible. Due to the free range of
research, pricing, and marketing, the U.S. market is the preferred
industry for major pharmaceutical companies.
This case note delves into the United States Supreme Court’s
recent decision in Caraco Pharmaceutical Laboratories, Ltd. v. Novo

develop the drug back within one year of the drug’s approval. Viagra continued to
do well, and in 2006 the drug made $1,600,000,000 in sales, representing 3.4% of
Pfizer's total revenue of $48,000,000,000 for 2006. See Alan Levin, Pfizer Inc.
Financial Report (2006). The drug continues to do well and in 2011, the drug made
$1,981,000,000 in revenue. See Frank D’Amelio, Pfizer Inc. Financial Report
(2011).
8
Select USA: Pharm Industry, supra note 1. The U.S. is home to the largest
and most innovative biopharmaceutical research in the entire world.
Biopharmaceutical Research Sector is Global Leader in Innovation, PHRMA,
http://www.phrma.org/about/biopharmaceuticals (last visited Jan. 25, 2013). The
FDA has approved more than three hundred million drugs in the past decade. Id.
Biopharmaceutical research has led to some of the most groundbreaking
discoveries in medicine, such as HIV medication, which has transformed the virus
from a death sentence into a manageable condition. Id.
9
Select USA: Pharm Industry, supra note 1.
10
MARCIA ANGELL, THE TRUTH ABOUT THE DRUG COMPANIES: HOW THEY
DECEIVE US AND WHAT TO DO ABOUT IT (2005). See also JOHN ABRAMSON,
OVERDOSED AMERICA: THE BROKEN PROMISE OF AMERICAN MEDICINE (2008)
(highlighting the various expenses associated with prescription drugs); SHANNON
BROWNLEE, OVERTREATED: WHY TOO MUCH MEDICINE IS MAKING US SICKER
AND POORER (2007) (touching on the costs of pharmaceuticals and health care).
11
See Select USA: Pharm Industry, supra note 1.
12
Id.
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Nordisk A/S, which closes a longstanding loophole whereby brand
name manufacturers publish overbroad “use codes” that overstate the
reach of their patents in Food and Drug Administration (FDA)
regulatory filings, thus preventing generic drug manufacturers from
supplying the drug at a much cheaper rate.13 Part II investigates the
historical and regulatory background of pharmaceutical drugs and the
stages they progress through (from clinical testing to the store
shelf).14 Part III addresses the major problem that has developed in
the pharmaceutical industry. Part IV states the facts of the lawsuit
between the parties Caraco and Novo, while Part V conducts an in
depth analysis on Justice Kagan’s majority opinion, followed by
Justice Sotomayor’s concurring opinion. Part VI discusses the legal
effects this case has had on the pharmaceutical industry and some
possible solutions to the FDA’s current drug approval situation,
which has proven to be largely inefficient and ineffective. Part VII
provides FDA counterarguments to the suggested solutions; and part
VIII addresses recent FDA and Congressional developments, while
part IX summarizes and concludes.
II. HISTORICAL BACKGROUND
The Food and Drug Administration15 is responsible for regulating
the manufacture, sale, and labeling of prescription drugs.16 If a

13

132 S. Ct. 1670 (2012).
Id.
15
The Food and Drug Administration (FDA) is “an agency within the U.S.
Department of Health and Human Services.” FDA Fundamentals, U.S. FOOD AND
DRUG
ADMINISTRATION,
http://www.fda.gov/AboutFDA/Transparency/Basics/ucm192695.htm (last visited
May 25, 2013). The agency has an “Office of the Commissioner and four
directorates overseeing the core functions of the agency: Medical Products and
Tobacco, Foods, Global Regulatory Operations and Policy, and Operations.” Id.
FDA is primarily tasked with protecting the health of the general public by assuring
the “safety, effectiveness, and security” of various drugs, foods, dietary
supplements and other various products consumed by human beings. Id. FDA is
also responsible for “protecting the public from electronic product radiation,
assuring cosmetics and dietary supplements are safe and properly labeled,
regulating tobacco products, and advancing the public health by helping to speed
product innovations.” Id. “FDA’s responsibilities extend to the 50 United States,
the District of Columbia, Puerto Rico, Guam, the Virgin Islands, American Samoa,
and other U.S. territories and possessions.” Id.
14
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company seeks approval from the FDA to sell a new drug, they must
first test the drug in the laboratory and on animals to determine
whether the drug is safe enough to be tested on humans.17 The
company then submits an Investigational New Drug Application
(IND) to the FDA. The FDA reviews the IND application and
determines whether to approve the application for testing on human
beings.18 Once the IND application is approved, the company will
initiate a Phase I study to assess the safety of the drug.19 The initial
testing phase typically lasts for several months and includes a test
group comprised of 20-to-100 paid volunteers. Scientists and
analysts study how the drug is “absorbed, metabolized, and excreted”
in human beings.20 Phase I also examines the side effects that occur
from taking the drug and whether the drug increases as higher
dosages are consumed.21
Once Phase I is complete and the drug is deemed safe, the
company will initiate Phase II of the clinical trial, which focuses on
the efficacy of the experimental drug.22 Phase II involves hundreds
of human patients and can last anywhere from a couple of months to
two years.23 Typically Phase II clinical studies are “blind studies”

16

How FDA Evaluates Regulated Products: Drugs, U.S. FOOD AND DRUG
ADMINISTRATION
(Apr.
04,
2012),
http://www.fda.gov/AboutFDA/Transparency/Basics/ucm269834.htm. The FDA
uses a series of data and methods to determine whether products are safe for
consumers. Id.
17
Id.
18
Id.
19
Overview
of
Clinical
Trials,
CENTER
WATCH
(2012),
http://www.centerwatch.com/clinical-trials/overview.aspx.
20
Id. According to Center Watch’s website: “About 70% of experimental
drugs pass this phase of testing.” Id.
21
Id.
22
Id. Although information gathered from “human trials are analyzed by a
team of experts before a drug is approved, it [is] impossible to anticipate all bad
reactions—especially very rare safety risks—unless they had also happened with
use of a similar drug.” Id. Further complicating matters is the fact that many of the
patients selected for the clinical trials are already sick and may be taking other
drugs simultaneously with the experimental drug.
23
Id.
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that incorporate control groups into the mix.24 Blind studies “allow
investigators to provide the pharmaceutical company and FDA with
comparative information about the relative safety and effectiveness
of the new drug.”25 If the experimental drug completes Phase I and II
testing, then Phase III begins. Phase III involves large scale testing
on hundreds to thousands of human patients and can span several
years in length.26 “This large-scale testing . . . provides the
pharmaceutical company and the FDA with a more thorough
understanding of the effectiveness of the drug . . . the benefits, and
the range of possible adverse reactions.”27
Once Phase III is complete,28 pharmaceutical companies are
required to compile their clinical testing data and send it to the
FDA’s Center for Drug Evaluation and Research (CDER) in a New
Drug Application (NDA).29 An NDA has several components as
required by 21 U.S.C. § 355 (b)(1), the first being: “(A) full reports
of investigations which have been made to show whether or not such
drug is safe for use and whether such drug is effective . . . .”30 The
report must also contain
(B) a full list of the articles used as components of
such drug; (C) a full statement of the composition of
such drug; (D)31 a full description of the methods used

Overview of Clinical Trials, supra note 19. Blind studies “mean that neither
the patients nor the researchers know who has received the experimental drug.” Id.
25
Id. It is estimated that only one third of experimental drugs successfully
complete Phase I and Phase II clinical trials.
26
Id.
27
Id. Ultimately the FDA is tasked with evaluating the pros and cons of a drug
and whether it is safe enough for enough for mass human consumption. Some of
the questions they consider are “if the [drug is] good for one person or a small
group, will it be good for the whole population? Which safety risks are likely to be
acceptable to patients who might take a drug and physicians who might prescribe
it?” How FDA Evaluates Regulated Products: Drugs, supra note 16.
28
Approximately “70% to 90% of drugs that enter Phase III studies
successfully complete this phase of testing.” Overview of Clinical Trials, supra
note 18.
29
How FDA Evaluates Regulated Products: Drugs, supra note 16.
30
21 U.S.C. § 355 (b)(1) (2012).
31
This is a statement describing the drug’s components and label, which
includes what the drug will be used to treat.
24
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in, and the facilities and controls used for, the
manufacture, processing, and packing of such drug.32
It must also contain: “(E) such samples of such drug and of the
articles used as components thereof as the Secretary may require; (F)
specimens of the labeling proposed to be used for such drug, and (G)
any assessments required . . . .”33 In addition to the NDA, the
manufacturer must also file “the patent number and the expiration
date of any patent which claims the drug . . .”34 and any other method
of use claims the manufacturer wishes to assert.35
Pursuant to 21 C.F.R. § 314.53, brand-name manufacturers must
provide descriptions of their method-of-use patents.36
These
descriptions are referred to as “use codes.” If the FDA approves a
new brand manufacturer’s drug, the Secretary will then publish the
information provided in the NDA, such as the patent number,
expiration of patents, descriptions of method-of-use patents, etc..
This information is informally known as the Orange Book, but
officially referred to as the “Approved Drug Products with
Therapeutic Equivalence Evaluations.”37 Unfortunately, the FDA

32

Id.
21 U.S.C. § 355 (b)(1) (2012).
34
Id. This information is part of The Drug Price Competition and Patent Term
Restoration Act of 1984; Establishment of a Public File and Request for
Comments, 50 Fed. Reg. 26791–01. The “Hatch–Waxman amendments” require
brand name manufacturers to publish this information so that generic drug
companies would know when the manufacturing patents expire. 21 U.S.C. § 355
(2012).
35
21 U.S.C. § 355 (b)(1) (2012). “The FDA may approve a brand-name drug
for multiple methods of use—either to treat different conditions or to treat the same
condition in different ways.” Caraco Pharm. Laboratories, Ltd. v. Novo Nordisk
A/S, 132 S. Ct. 1670, 1676 (2012). The applicant also has the opportunity to
amend their NDA if they receive a patent after they file the NDA but before the
FDA approves the application. See 21 U.S.C. § 355 (b)(1).
36
See 21 C.F.R. §§ 314.53(c)(2)(ii)(P)(3), (e) (2011).
37
Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1676. This is list is referred
to as the “Orange Book” because of “its orange colored cover.” 68 Fed. Reg.
36676–01 (June 18, 2003).
33

Journal of the National Association of Administrative Law Judiciary

350

33-1

“does not attempt to determine if that information is accurate.”38
Rather, the FDA assumes the information is completely accurate.39
Once this process is completed, other companies seeking
permission to sell a generic version of the drug may do so by filing
an Abbreviated New Drug Application (ANDA).40 The ANDA has
several requirements and is specifically designed to expedite low-cost
generic versions of brand-name drugs into the market, so that more
people can afford to use the drug.41 Instead of conducting
independent studies to obtain evidence on the generic drug’s safety
and efficacy, ANDA applicants will typically show that the generic
drug has the same active ingredients and is “biologically equivalent
to the brand-name drug.”42 ANDA applicants will also demonstrate
“that the conditions of use prescribed, recommended, or suggested in
the labeling proposed for the new drug have been previously
approved for a [listed drug].”43 FDA is prohibited from approving an
ANDA application that would infringe on a patent, and thus the
timing of when a generic drug will be approved is based on the
“scope and duration” of patents in place for the brand-name drug.44
As discussed prior, there are two types of patents: (1) that protects
the actual drug compound; and (2) that protects the brand
manufacturer’s rights to a specific method-of-use.45

38

Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1676. The FDA
“determined that it is more efficient and accurate to ask the NDA holder to give us
the exact use code description to be published in the Orange Book.” 68 Fed. Reg.
36676–01 (June 18, 2003).
39
Id.
40
See 21 U.S.C. § 355 (j)(2)(A) (2012).
41
Previously recognized in Eli Lilly & Co. v. Medtronic, Inc., 496 U.S. 661,
676 (1990).
42
Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1676.
43
21 U.S.C. § 355 (j)(2)(A)(i). This is basically a short cut to getting the
FDA’s approval. A “listed drug” means that it has already been published in the
FDA’s Orange Book and has already received FDA approval, meaning it has gone
through all the required testing phases. Id.
44
Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1676. The FDA cannot
approve an ANDA application for a generic version of a drug if the brand name
company still holds a valid patent on the drug compound. Id.
45
Id. The method-of-use patent can continue long after the drug compound
patent has expired (A drug compound patent usually lasts between five and
fourteen years.).
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After the generic company consults the Orange Book, they must
file the ANDA and convince the FDA that its generic drug will not
infringe on any of the brand-name drug manufacturer’s patents.46 In
the case where all of the brand-name drug manufacturer’s patents
have expired (or will expire prior to the generic drug’s approval) or
are not listed in the Orange Book, the generic drug manufacturer
simply states that information, and the ANDA is approved.47
If the brand-name manufacturer’s patents have not yet expired,
there are two methods of certification the generic manufacturer can
pursue. The first option is that the generic company can submit a
section viii (“section viii”) statement asserting that they will market
the drug for one or more methods that are not covered by the brand
name drug company’s patents.48 Typically a generic drug company
will file a section viii statement when the brand-name drug
company’s drug compound patent has expired, and only a method-ofuse patent still exists.49 If the generic drug company elects to pursue
a section viii route, they will propose, “labeling for the generic drug
that ‘carves out’ from the brand's approved label the still-patented
methods of use.”50 The FDA will under no circumstances approve an
ANDA if the generic brand’s modified label overlaps with any of the
brand name’s use code.51 As mentioned prior, the FDA assumes the
brand’s use code accurately describes the methods-of-use and does
not conduct its own independent research to confirm any of this

46

Id.
See 21 U.S.C. §§ 355(j)(2)(A)(vii)(I)–(III) (2012).
48
See 21 U.S.C. § 355(j)(2)(A)(viii) (2012).
49
See supra note 33–35.
50
Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1677. The expression
“carved out” refers to removing patented methods of use from the new modified
label that the generic drug company is proposing. The FDA is allowed to approve
a generic drug’s modified version of the brand name’s label (as long as it does not
include patented methods-of-use), which is an exception to the normal rule that
states a generic drug label must have the same label as the brand name. See 21
U.S.C. §§ 355(j)(2)(A)(v), (j)(4)(G) (2012).
51
See Applications for FDA Approval to Market a New Drug: Patent
Submission and Listing Requirements, 68 Fed. Reg. 36676, 36682–83 (June 18,
2003). There can be absolutely no overlap of the generic drug’s label with the
brand name company’s label if the brand name company still has a valid patent on
a method for using the drug.
47
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information.52 Thus, whether section viii is available to a generic
drug company hinges on how the brand name drug company
describes its various patents.53 Interestingly, if the FDA determines
there is enough space for the generic manufacturer’s proposed label,
then it will approve the ANDA application.54
The second option for a generic drug manufacturer is that it can
choose to file a paragraph IV (“paragraph IV”) certification, which in
essence provides the patent is “invalid or will not be infringed by the
manufacture, use, or sale of the [generic] drug.”55 A generic drug
manufacturer will choose to file a paragraph IV certification in two
scenarios. The first scenario is if the company wants to market and
sell the generic drug for all purposes, instead of “carving out” the
options that are still “supposedly” under patent.56 The second
scenario is if the generic drug manufacturer is unable to avoid an
overlap with the brand name company’s use code, despite having
carved out various uses.57 Filing a paragraph IV certification leaves
the generic brand company vulnerable to litigation because the patent

52

Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1677. According to the
FDA, it “lacks ‘both [the] expertise and [the] authority to review patent claims;
although it will forward questions about the accuracy of a use code to the brand, its
own ‘role with respect to patent listing is ministerial.’” Applications for FDA
Approval, 68 Fed. Reg. at 36683 (June 18, 2003). This creates a vicious ineffective
circle for drug approval. Basically, the brand manufacturer submits a description
claiming a particular approved use for the drug, and the FDA in turn sends the
description back to the brand company and asks that they make sure the description
is accurate. The FDA is essentially asking the brand manufacturers to police the
accuracy of their own use code descriptions. A brand manufacturer submitting an
overbroad use code so that a generic form of the drug cannot be produced is never
going to openly admit to FDA that their use code is overly broad and inaccurate.
Furthermore, the FDA believes “its scarce resources would be better utilized in
reviewing applications rather than reviewing patent claim.” Abbreviated New
Drug Application Regulations: Patent Exclusivity Provisions, 59 Fed. Reg. 50,338,
50,343 (Oct. 3, 1994).
53
Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1677.
54
Id.
55
21 U.S.C. § 355(j)(2)(A)(vii)(IV) (2012). Filing a paragraph IV certification
can almost guarantee that the brand name company will sue the generic company
for patent infringement. See infra note 51.
56
Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1677.
57
Id. See supra note 50 for explanation of “carving out.”
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statute58 considers the filing of a paragraph IV certification to be an
act of infringement, giving the brand name company a valid cause of
action.59 If the brand manufacturer chooses to file a lawsuit against
the generic manufacturer for filing a paragraph IV certification,60 the
FDA may not approve the generic company’s ANDA for up to thirty
months or until a final judgment on the lawsuit has been entered.61
Filing a paragraph IV certification has both pros and cons because
although it exposes the generic company to potential litigation, the
end result could allow the generic drug manufacturer to sell its drug
for all uses approved by the FDA.62
III. THE PROBLEM
At the end of the 20th century, evidence began to surface that
numerous brand name drug companies were exploiting the statutory
structure in order to prevent generic drug companies from certifying
their drug, or at least significantly delaying the drug’s appearance on
the pharmaceutical market.63 Sure enough, the Federal Trade
Commission (FTC) published a study detailing these practices in July
of 2002.64 The FTC study focused its attention on brand name drug
The “patent statute” is 35 U.S.C. § 271, and explains when a patent is
considered to be infringed upon and the available and appropriate courses of action.
See generally 35 U.S.C. § 271 (2010).
59
See 35 U.S.C. § 271(e)(2)(A). “It shall be an act of infringement to submit
an application under section 505(j) of the Federal Food, Drug, and Cosmetic Act . .
. for a drug claimed in a patent or the use of which is claimed in a patent.” Id. The
valid cause of action in this situation will be a lawsuit against the generic
manufacturer for infringing a valid patent.
60
If a generic company files a paragraph IV certification, the brand name
company has forty-five days to bring an action for infringement against the party.
Id.
61
See 21 U.S.C. § 355(j)(5)(B)(iii) (2012).
62
Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1677–78.
63
Id.
64
General Drug Entry Prior to Patent Expiration: An FTC Study, FEDERAL
TRADE
COMM’N
(July
2002),
available
at
http://www.ftc.gov/os/2002/07/genericdrugstudy.pdf [hereinafter FTC Study]. The
Hatch–Waxman Amendments to the Federal Food Drug and Cosmetic Act
substantially altered the way in which generic drugs receive market approval from
the FDA. The Hatch–Waxman Amendments helped speed up the procedures for
allowing generic drugs to be sold on the open market, and without a doubt greatly
58
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manufacturing companies that were submitting inaccurate patent
information to the FDA, in order to prevent generic drugs from
coming to market.65 In Mylan, a brand name drug manufacturer had
listed a new patent just prior to the expiration of their original drug
compound patent.66 The new patent did not cover the drug’s
compound or its method of uses, however the brand name drug
manufacturer was still able to extend its rights over the drug.67 The
generic manufacturer sued the brand name manufacturer and wanted
them to remove their improper description listed in the Orange Book.
However, the Federal Circuit Court of Appeals found that the HatchWaxman Amendments did not provide for this type of solution.68
The FTC found, that as a result of the ruling in Mylan, generic
manufacturers in Mylan’s predicament only had one option, which
was to file a paragraph IV certification and wait for the thirty-month
waiting period to expire.69 Once thirty months had expired, the FDA
could approve the ANDA.70

increased the amount of generic drugs in the market. Id. In fact, at the time the
FTC finished conducting their study in 2002, they reported that generic drugs
comprised more than forty seven percent of the prescriptions filled in the U.S.,
which was an enormous increase from nineteen percent in 1984 when Hatch–
Waxman was first implemented. Id. Despite Hatch–Waxman’s success, there were
several provisions in the act that allowed for certain strategies to be used by brand
name pharmaceutical manufacturers to hinder the availability of generic drugs. Id.
The FTC study in 2002 took on the task of investigating whether the publication of
overbroad use patents by brand name pharmaceutical manufacturers represented
more isolated instances, or typical measures taken by manufacturers to ensure a
generic form of the drug could not be brought to market. Id.
65
Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1678. The FDA was
treating the patent information submitted to them as true and correct; they never
conducted any independent due diligence to ensure the descriptions were accurate.
Id.
66
See Mylan Pharm., Inc. v. Thompson, 268 F.3d 1323 (Fed. Cir. 2001).
67
Id. The Federal Circuit in Mylan found that delisting the patent (removing
the patent completely) was not a proper remedy under the Hatch–Waxman
Amendments. Id. However, the decision in Mylan alerted Congress to a major
problem. Id. Generic companies basically had no way of challenging inaccurate
patent listings, thus the FDA was unable to approve applications for a generic form
of the drug. Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1687.
68
Mylan Pharm., Inc., 268 F. 3d at 1323.
69
See FTC Study, supra note 64, at 41–45.
70
Id.
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In response to this abuse, Congress created a legal counterclaim
for generic drug manufacturers to contest incorrect and overbroad
patent information that brand name manufacturers submit to the
FDA.71
Congress passed the Medicare Prescription Drug,
Improvement, and Modernization Act of 2003, which allows generic
drug manufacturers to:
assert a counterclaim seeking an order requiring the
[brand manufacturer] to correct or delete the patent
information submitted . . . on the ground that the
patent does not claim either -- (aa) the drug for which
the application was approved or (bb) an approved
method of using the drug.72
Essentially, the counterclaim allows a generic drug manufacturer
to obtain a judgment in their favor, instructing the brand name drug
manufacturer to “correct or delete” their overbroad or incorrect
description regarding the patent, which is preventing FDA from
certifying the generic manufacturer’s drug.73
IV. FACTS
The petitioner seeks to sell and the respondent sells the popular
diabetes drug repaglinide,74 which is commonly used to treat type
two diabetes.75 Repaglinide is a pharmaceutical drug that helps

71

Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1678.
21 U.S.C. § 355(j)(5)(C)(ii)(I) (2012). See also Medicare Prescription Drug,
Improvement, and Modernization Act of 2003, Pub. L. No. 108–173 (2003). The
Medicare Prescription Drug, Improvement, and Modernization Act is a federal law
that was enacted in 2003; its primary purpose was to help make prescription drugs
more affordable for Americans, especially for senior citizens.
73
Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1678.
74
Consumer Medication Information: Repaglinide, U.S. NATIONAL LIBRARY
OF
MEDICINE
(Apr.
15,
2011),
http://www.ncbi.nlm.nih.gov/pubmedhealth/?term=repaglinide.
75
Type two diabetes is the most common form of diabetes, and millions of
Americans suffer from this condition. American Diabetes Association: Type 2,
AMERICAN DIABETES ASSOCIATION, http://www.diabetes.org/diabetes-basics/type2/ (last visited May 25, 2013). Type two diabetes is a condition where the body is
unable to produce enough insulin. Id. Insulin is essential to the human body
72
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balance the amount of glucose (sugar) in the human body. 76 It works
to decrease the overall amount of glucose in the blood by stimulating
the release of insulin from the pancreas.77 Novo, respondent in this
case, manufactures the brand name version of repaglinide called
Prandin.78 The FDA approved three uses for Prandin in order to treat
type two diabetes: “repaglinide by itself; repaglinide in combination
with metformin; and repaglinide in combination with
thiazolidinediones (TZDs).”79 Novo is a worldwide leader in
diabetes care and obtained the original patent over the repaglinide
drug compound, “known as the ‘035 patent.”80 Their drug compound
patent expired in 2009, but in 2004 Novo obtained a method-of-use
patent for repaglinide to be used in combination with metformin
(“‘358 patent”), which does not expire until 2018.81 Novo only held
one patent for the three FDA approved methods of use for
repaglinide at the time the Supreme Court granted certiorari.82
Caraco, petitioner in this case, seeks to sell a generic version of
the drug repaglinide for two of the three above-mentioned purposes.83
In 2005 the company filed an ANDA with the FDA so that they
could sell a generic brand version of repaglinide.84 At this time,

because it helps the body use glucose for energy. Id. When you consume food, the
body breaks down all of the sugars and starches into glucose for the body’s cells to
use as energy. Id. Insulin helps get the sugar from the blood into the cells. Id.
Serious problems arise when there is a build up of glucose in the blood. Id.
76
Consumer Medication Information: Repaglinide, U.S. NATIONAL LIBRARY
OF
MEDICINE
(Apr.
15,
2011),
http://www.ncbi.nlm.nih.gov/pubmedhealth/?term=repaglinide.
77
Id. The pharmaceutical drug comes in a tablet form and is usually ingested
thirty minutes before or after a meal. Id.
78
Id.
79
Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1678.
80
Id.
81
Id. Novo’s ‘358 patent is the patent at issue in this case and “claims a
method for treating diabetes by administering . . . repaglinide in combination with
metformin.” Id.
82
Id. at 1679. At the time certiorari was granted by the Supreme Court, Novo
held no patent for the use of repaglinide with thiazolidinediones or its use alone.
Id.
83
Id.
84
Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1679. In 2005, when
Caraco filed its ANDA, “Novo's use code for the ‘358 patent represented that the
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Novo held a patent on the drug compound for Prandin, which was
listed as patent ’035 as well as a method-of-use patent for Prandin’s
use with metformin, which was listed as patent ‘358.85 At the time
Novo filed the ANDA, they informed the FDA that they would not
market their new generic form of the drug until after the drug
compound patent ‘035 had expired in 2009.86 As for the remaining
‘358 patent, Caraco filed a paragraph IV certification stating that
patent ‘358 was “invalid or would not be infringed [upon].”87 As
soon as Caraco filed their ANDA application and paragraph IV
statement, Novo treated the filing as an infringement on the ‘358
patent and immediately initiated a lawsuit against Caraco.88
The FDA advised Caraco that if they were not planning on
marketing the drug repaglinide for the use with metformin, it should
submit a section viii statement instead, which would allow Caraco to
sell the drug for the other two uses of repaglinide that were not
patented by Novo.89 Caraco took the FDA’s advice and filed a
section viii statement in 2008, and carved out90 the patented methodof-use from their generic drug’s label.91 However, right before the
FDA approved Caraco’s section viii filing, Novo changed its use
code description for the ‘358 patent, which described “a method for
improving glycemic control in adults with type two diabetes.”92 The
newly altered code indicated that Novo’s ‘358 patent protected all
three methods-of-use for repaglinide that were approved by the FDA
to treat diabetes, making Caraco’s carved out label of uses
insufficient.93 Caraco’s label now overlapped with Novo’s use code
on two of the uses approved by the FDA; Caraco was unable to carve
patent covered ‘use of repaglinide in combination with metformin to lower blood
glucose.’” Id.
85
Id.
86
Id.
87
21 U.S.C. § 355(j)(2)(A)(vii)(IV) (2012).
88
Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1679.
89
Id.
90
Id. In 2008, Novo still had a patented method of use for repaglinide and
metformin to be used together. See also supra note 50 explaining “carving out.”
91
Id.
92
Novo Nordisk A/S v. Caraco Pharm. Laboratories, Ltd., 601 F.3d 1359,
1363 (Fed. Cir. 2010).
93
Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1679.
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out these two uses because, if they did, there would be no other uses
left to market or sell.94 As mentioned prior, the FDA had only
approved repaglinide for three uses, all of which were encompassed
by Novo’s newly updated use code patent ‘358.95 As a result of
Novo’s updated use code description, the FDA informed Caraco that
it could no longer file a section viii statement seeking market
approval for their generic drug.96
Caraco immediately responded to Novo’s infringement lawsuit
by filing a statutory counterclaim against them.97 “The counterclaim
sought an order98 requiring Novo to ‘correct’ its use code ‘on the
grounds that the ‘358 patent does not claim’99 two approved methods
of using repaglinide—alone and in combination with TZD’s.”100 The
U.S. District Court for the Eastern District of Michigan ruled in favor
of Caraco, thus granting their motion for summary judgment. 101 The
District Court found that “Novo [had] improperly filed with the FDA
for listing in the Orange Book the use code narrative for the method
of use of the [‘358] patent.”102 Therefore, “Caraco was entitled to a
mandatory injunction requiring Novo to request FDA to delist [its
new listing,] and reinstate its former . . . listing.”103 Despite the
District Court’s ruling, the U.S. Federal Circuit Court of Appeals
found that “Caraco Pharmaceutical Laboratories, Ltd. does not have a
statutory basis to assert a counterclaim requesting such injunctive

94

Id.
Id.
96
Id.
97
Id.
98
The order sought by Caraco “would permit the FDA to accept Caraco's
proposed carve–out label and approve the company's ANDA.” Caraco Pharm.
Laboratories, Ltd., 132 S. Ct. at 1679.
99
See 21 U.S.C. § 355(j)(5)(C)(ii) (2012).
100
Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1679. The counterclaim
would permit the FDA to approve Caraco’s ANDA and carved out label.
101
Id.
102
Novo Nordisk A/S v. Caraco Pharm. Laboratories, Ltd., 656 F. Supp. 2d
729, 730 (E.D. Mich. 2009). The district court’s ruling would have forced Novo to
delist its new patent description and reinstate its former patent description, thus
allowing Caraco to file its section viii.
103
Id.
95
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relief,” and therefore it reversed and vacated the injunction.104 The
Federal Circuit Court of Appeals analyzed 21 U.S.C. § 355, which
allows for a generic company to file a counterclaim. The statute
states that: “ANDA applicant may assert a counterclaim seeking an
order requiring the holder to correct or delete the patent information .
. . on the ground that the patent does not claim either (aa) the drug for
which the applicant was approved or (bb) an approved method of
using [it].”105
The Federal Circuit Court of Appeals interpreted the information
in (bb) to mean that Caraco was required to demonstrate that “the
‘358 patent [did] not claim any approved method of use.”106 The
Federal Circuit reiterates that a counterclaim can only be authorized
if the “listed patent does not claim any approved methods of using
the listed drug.”107 They held that because Novo’s patent covered
one method-of-use (repaglinide with metformin), the statutory
counterclaim was unavailable to Caraco.108 The court also ruled that
the “counterclaim provision does not reach use codes because they
are not ‘patent information submitted by the [brand] under subsection
(b) or (c).’”109 Caraco filed a writ of certiorari with the United States
Supreme Court, which was granted on June 27, 2011.110

104

Novo Nordisk A/S v. Caraco Pharm. Laboratories, Ltd., 601 F.3d 1359,
1360 (Fed. Cir. 2010).
105
See 21 U.S.C. § 355 (j)(5)(C)(ii)(I) (2012).
106
Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1679. The Federal Circuit
Court found that “[a]n approved method means any approved method.” Id. at
1680. Since “the patent covers one approved method of use—repaglinide in
combination with metformin—the counterclaim was unavailable [to Caraco].” Id.
107
Novo Nordisk A/S, 601 F.3d at 1365.
108
Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1680.
109
Id. The Federal Circuit believed the patent information submitted consists
only of the patent number and expiration date. Id. Judge Dyk disagreed and wrote
a dissenting opinion. Dyk “would have read the phrase ‘the patent does not claim .
. . an approved method of using the drug’ to include situations where, as here, the
use code wrongly indicates that the patent covers one or more particular approved
methods of use.” Id. (Dyk, J., dissenting). Furthermore, “he would have construed
‘patent information submitted . . . under subsection (b) or (c)’ to include use
codes.” Id. (Dyk J., dissenting). Ultimately, the Supreme Court granted certiorari
and sided with Judge Dyk.
110
Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1680. First, the Supreme
Court was tasked with deciding when a “patent does not claim . . . an approved
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V. ANALYSIS OF OPINION
A. Judge Kagan’s Majority Opinion
Recognizing the importance of the statutory language in 21
U.S.C. § 355, Justice Kagan’s opinion begins with an analysis of two
statutory phrases against the backdrop of a third statutory phrase.111
After a thorough review of the statutory language, Justice Kagan
determined that the “statute permits a counterclaim whenever a
patent does not claim a method of use for which the ANDA applicant
seeks to market the drug.”112 She also determined that the
counterclaim provides a way to correct the overbroad use codes by
deleting or correcting the use code description.113 Next, Justice
Kagan addressed and dismissed Novo’s claim that the Court would
be resurrecting a bill that Congress previously did not support, as
Congress failed to pass S. 812,114 which would have allowed a

method of using’ a drug. Second, [the Court had to] determine the content of
patent information submitted . . . under subsection (b) or (c) of § 355.” Id.
111
Id.
The third statutory phrase is the remedy for a prevailing
counterclaimant, which is to either “correct or delete” the inaccurate patent. Id.
When the Supreme Court conducts statutory interpretations, they take into
consideration several factors, such as the language of the statute itself, the context
the language is being used in, and the broader context of the statute as a whole. See
Robinson v. Shell Oil Co., 519 U.S. 337 (1997).
112
Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1683. In her opinion,
Justice Kagan conceded that the counterclaim clause of the Medicare Prescription
Drug, Improvement, and Modernization Act of 2003 was confusing and not
entirely clear. However, when the Court considered the statutory text and context
together, they concluded, “a generic manufacturer in Caraco's position can use the
counterclaim.” Id. at 1681.
113
Id. at 1684.
114
Greater Access to Affordable Pharmaceuticals Act of 2002, S. 812, was a
Congressional Senate Bill sponsored by Senator Charles Schumer and was
introduced on May 1, 2001. Greater Access to Affordable Pharmaceuticals Act of
2002, S. 812, 107th Cong. (2002). S. 812 would have required pharmaceutical
companies to register their patents with the FDA within thirty days of approval and
would have allowed a generic company to challenge an overbroad patent
description by filing a separate civil action. Id. at 8. The bill also would have
allowed for the importation of prescription drugs into the United States from
Canada. Id. The bill was never enacted into law. Id.
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generic company to challenge an overbroad patent description.115
Finally, Justice Kagan and the Court rejected the argument that
Congress enacted the counterclaim only to solve problems similar to
those in Mylan.116 Justice Kagan and the Court ultimately decided
that Caraco was allowed to bring a counterclaim, which requested
Novo to correct its use code on the ground that the patent did not
claim an approved method of use for the drug.117
1. A Company May Bring a Counterclaim to Show That a
Method of Use is Unpatented.
A company that submits an ANDA application to the FDA and is
subsequently sued for patent infringement may bring a counterclaim
“on the ground that the patent does not claim an approved method of
using the drug.”118 Both Caraco and Novo debate the true meaning
of this language, with each interpretation resulting in a drastically
different outcome.119 Novo argues that “not an” means “not any,”
which means the counterclaim would only be available if the patent
does not claim any approved method for using the drug.120 If this
were the true meaning, Caraco would be unable to bring a
counterclaim against Novo because Novo’s ‘358 patent claims the
use of repaglinide with metformin.121 Unsurprisingly, Caraco
advocates for a different interpretation and takes “not an” to mean
“not a particular one,” meaning the statute allows for a counterclaim
whenever the ANDA applicant does not seek to market the drug
under a method of use already claimed by another company’s
patent.122 Caraco’s view would allow for use of the counterclaim
because “Novo’s ‘358 patent does not claim the use of repaglinide
with TZDs or its use alone.”123 The Supreme Court engages in a

115

Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1684.
See infra notes 168–72.
117
See infra notes 181–83.
118
Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1681.
119
Id.
120
Id.
121
Id.
122
Id.
123
Id.
116
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comical analysis of what “not an” means and ultimately sides with
Caraco’s interpretation.124
The Court explained that an approved drug might have multiple
uses, not all of which are covered by a patent.125 The Hatch-Waxman
Amendments permits the FDA to approve applications for companies
that wish to market generic forms of drugs for unpatented uses.126
Essentially, the statutory scheme envisions that a patented use for a
particular drug will not bar the marketing of a generic form for an
unpatented use.127 Generic manufacturers use the counterclaim to
challenge an overbroad assertion of rights by brand name
manufacturers.128 Thus, the Court found that the “availability of the
counterclaim matches the availability of FDA approval under the
statute: A company may bring a counterclaim to show that a method
of use is unpatented because establishing that fact allows the FDA to
authorize a generic drug via section viii.”129

124

Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1681. The Supreme Court
took the position that the answer to the question “what does not an mean?” is “it
depends.” The Court strongly believes that context determines the meaning of
words, and gives various everyday life scenarios to demonstrate this. Id.
Sometimes “not an” means “not any.” Id. “If your spouse tells you he is late
because he ‘did not take a cab,’ you will infer that he took no cab at all (but took
the bus instead).” Id. Furthermore, “if a sports-fan friend bemoans that ‘the New
York Mets do not have a chance of winning the World Series,’ you will gather that
the team has no chance whatsoever (because they have no hitting).” Id. However,
the Court points out that other times “not an” means “not a particular one.” Id.
“Suppose your spouse tells you that he got lost because he ‘did not make a turn.’
You would understand that he failed to make a particular turn, not that he drove
from the outset in a straight line.” Id. Furthermore, “suppose your child explains
her mediocre grade on a college exam by saying that she ‘did not read an assigned
text.’ You would infer that she failed to read a specific book, not that she read
nothing at all on the syllabus.” Id. The Court comically communicates that
CONTEXT MATTERS!
125
Id. An approved drug may have multiple uses. See, e.g., 21 U.S.C. §
355(b)(1) (2012) (requiring that an NDA applicant file information about “any
patent which claims the drug . . . or which claims a method of using such drug”).
Id.
126
Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1681. In other words, the
statutory scheme “contemplates that one patented use will not foreclose marketing
a generic drug for other unpatented ones.” Id. at 1682.
127
Id.
128
Id. at 1681.
129
Id.
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The Court highlights that under section 355, the FDA could
approve Caraco’s ANDA application so long as Novo does not
possess a patent covering the uses listed in Caraco’s ANDA
application.130 However, Novo argues that since they have a valid
patent on one of the three approved uses, Caraco’s counterclaim
disappears; the Court completely disagrees with Novo’s position.131
Novo further argues that Congress could have “imposed additional . .
. qualifications on the term ‘an approved method of use’ and indeed
did so in another place in the statute.”132 The Court responds by
saying the mere possibility that Congress could have provided clearer
phrasing does not outweigh the natural reading of the statute.133 If
this were true, courts today would interpret most of the statutes
passed by Congress in a much different way.134 However, the Court
does not wish to focus on the possibility that Congress could provide
clearer language in the statute, rather it believes the words “not any”
do not appear in the counterclaim provision because Congress did not

130

Id. If Caraco does not try to patent a use already claimed by Novo, then the
FDA could approve Caraco’s ANDA application “regardless whether a patent
protects yet a third method of using the drug.” Id. Novo even “agrees that Caraco
could bring a counterclaim if Novo's assertion of patent protection for repaglinide
lacked any basis—for example, if Novo held no patent, yet claimed rights to the
pair of uses for which Caraco seeks to market its drug.” Id.
131
Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1681.
132
Id. at 1682. Novo points to “section viii itself, which applies when the
brand's patent ‘does not claim a use for which the ANDA applicant is seeking
approval.’” Id. See 21 U.S.C. § 355(j)(2)(A)(viii) (2012).
133
Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1682. The Supreme Court
elaborates and said that if the possibility of clearer phrasing could outweigh the
statute’s most natural reading, then courts would interpret most statutes today much
differently. They also turn Novo’s argument around on itself and highlight that
“Congress could have more clearly expressed Novo’s proposed meaning in the
easiest of ways—by adding a single letter to make clear that ‘not an’ really means
‘not any.’” Furthermore, Congress used a “not any” in the very next subclause.
See 21 U.S.C. § 355(j)(5)(C)(ii)(II) (“Subclause (I) does not authorize the assertion
of a claim . . . in any [other] civil action.”). The Court believes Congress knew
how to say “not any” and would have used the word “not any” if that was the
meaning they intended, and that this “sees, raises, and bests Novo’s argument.”
Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1682.
134
Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1682.

Journal of the National Association of Administrative Law Judiciary

364

33-1

intend what Novo wishes they had.135 Instead, the Court believes
that Congress intended the counterclaim provision of the HatchWaxman Amendments to fit within the overall statutory scheme.136
Fitting into the overall statutory scheme would mean that Congress
created the counterclaim in order to assist in the approval of noninfringing generic drugs by the FDA.137
2. Patent Information Submitted Under 21 U.S.C. §§ 355 (b), (c)
Includes Use Codes.
Next, Novo argues that Caraco’s counterclaim fails for another
reason because the counterclaim is unable to provide a way “to
correct use codes because they are not ‘patent information’ submitted
by the brand under subsection (b) or (c) of [U.S.C] § 355.”138 The
Court addresses the first part of Novo’s contention by highlighting
that although the statute does not define “patent information,” a use
code must still qualify.139 The statute does require a company (Novo
in this situation) to describe the method-of-use claimed in their
patent.140 The Court finds this to be sufficient to fit under the
Id. Novo wishes that Congress had intended to use the words “not any”
because that would mean the FDA would be unable to approve Caraco’s ANDA
application because Novo holds a valid patent over one of the approved uses. Id.
If Novo’s reading of the statute were true, the FDA would only be able to approve
Caraco’s application if Novo did not have one single valid patent. Id.
136
Id.
137
Id. at 1683.
138
Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1683. The Court once
again disagrees with Novo’s argument and sides with Caraco. Id.
139
Id.
140
Id. See 21 C.F.R. § 314.53(c)(2)(ii)(P)(1)(2)(3), which requires a company
to include in its published information regarding its patent:
135

Information on each method-of-use patent including the
following: (1) Whether the patent claims one or more approved
methods of using the approved drug product and a description of
each approved method of use or indication and related patent
claim of the patent being submitted; (2) Identification of the
specific section of the approved labeling for the drug product that
corresponds to the method of use claimed by the patent
submitted; and (3) The description of the patented method of use
as required for publication.
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ordinary understanding of the language, and it is the “submitted
under” phrase that presents the more difficult question.141 21 U.S.C.
§ 355 (b), (c), “require an NDA applicant to submit specified
information: ‘the patent number and the expiration companies to
submit use codes.142 The Court gives “under” a broad meaning in
finding that “use codes fall within the counterclaim’s ambit if the
phrase ‘submitted under’ reaches filings that not only subsections (b)
and (c) themselves, but also their implementing regulations
require.”143 The date of any “patent claiming the drug or a method of
its use.”144 Novo contends only that information accompanies the
counterclaim provision.145 However, both (b) and (c) of section 355
oversee the regulatory process in which brand name companies
provide additional patent information to the FDA, prior to and after
the approval of an NDA.146 Specifically, those subsections require
brand Court believes the scope of the term “under” becomes
principally clear when compared with other phrases such as
“described in” and “prescribed by,” which appear in neighboring

Id.
141

Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1683.
Id. The FDA’s principal legal authority was section 505 of the Food Drug
and Cosmetic Act and 68 Fed. Reg. 36697–36698, which defines the FDA’s
general rulemaking authority.
143
Id. Several Supreme Court cases support giving the word “under” a broad
meaning. See Eli Lilly & Co. v. Medtronic, Inc., 496 U.S. 661 (1990), in which the
Court examined a similar statutory reference under 35 U.S.C. § 271(e)(1) that
discussed “submission of information under a Federal law which regulates the
manufacture, use, or sale of drugs.” Caraco Pharm. Laboratories, Ltd., 132 S. Ct.
at 1683. The Court found that submitting information under a ‘Federal Law’
“suggests doing so ‘in furtherance of or compliance with a comprehensive scheme
of regulation.’” Id. at 1684 (citing Eli Lilly, 496 U.S. at 667). The Court in Caraco
too believes that “[p]atent information submitted . . . under subsection (b) or (c)”
most naturally refers to patent information provided as part of the “comprehensive
scheme of regulation” premised on those subsections. Id. Also in Ardestani v.
I.N.S., 502 U.S. 129, 131 (1991), the Court held that a “regulatory proceeding
‘under section 554,’. . . meant any proceeding ‘subject to,’ ‘governed by,’ or
conducted ‘by reason of the authority of’ that statutory provision.” Id.
144
Id.
145
Id.
146
Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1683.
142
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provisions.147 These phrases typically signify a patent number and
expiration date. The Supreme Court contrasts this with the word
“under,” which they believe naturally “reaches beyond [the] most
barebones information of [a patent number and expiration date] to
other patent materials the FDA demands in the regulatory
process.”148
The Court found that Congress’s decision once again fits the
broader statutory context, as use codes are crucial to the
implementation
of
the
Hatch-Waxman
Amendments.149
Furthermore, use codes are no less important because an FDA
regulation rather than a statute requires their submission.150 The
Hatch-Waxman Amendments helped speed the process by which a
generic drug could be brought to market by requiring FDA to
approve an ANDA application that is filed with a section viii
statement, when a company seeks to market a generic form of a drug
for unpatented methods of use.151 In order for the FDA to determine
whether a patent covers a specific method of use, they refer to the
“Orange Book,” which contains all the use codes submitted by drug
companies during the regulatory process of bringing their drug to
market.152 The Court points out that if the use codes submitted to
FDA and published in the “Orange Book” are overly broad, it
prevents FDA from approving ANDAs.153

147

Id. An example of these different phrases can be found in 21 U.S.C.
§355(d)(6) (2012).
148
Id.
149
Id. The FDA explains how “[u]se codes are intended to alert ANDA and
505(b)(2) applicants to the existence of a patent that claims an approved use. They
are not meant to substitute for the applicant's review of the patent and the approved
labeling.” 68 Fed. Reg. 36676–01 (June 18, 2003).
150
See 68 Fed. Reg. 36676–01 (June 18, 2003), which states that “[u]se codes
are intended to alert ANDA and 505(b)(2) applicants to the existence of a patent
that claims an approved use.” Id.
151
Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1684.
152
Id.
153
Id. “An overbroad use code . . . throws a wrench into the FDA's ability to
approve generic drugs as the statute contemplates. So it is not surprising that the
language Congress used in the counterclaim provision sweeps widely enough to
embrace that filing.” Id.
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3. The Counterclaim Does Provide Remedies for Incorrectly
Published Use Codes.
As mentioned prior, Novo contends that the counterclaim does
not provide a way in which to correct overbroad use codes.154
Section 355 clearly states that an “applicant [may] assert a
counterclaim seeking an order requiring the [holder] to correct or
delete the patent information.”155 The Court interprets the statute to
provide for two remedies: a brand company may either (1) correct or
(2) delete its incorrect patent information from the Orange Book.156
Novo argues that the counterclaim is purely a delisting provision and
can only “correct erroneous patent numbers.”157 Novo provides the
Court with an example: if Novo mistakenly listed their patent number
as ‘359 instead of ‘358 when submitting their drug patent information
for publication in the Orange Book, then Caraco could bring a
counterclaim and require Novo to “correct” its incorrect listing.158
The Court seriously doubts that Congress enacted a counterclaim
provision to correct a minor error159 such as the mislabeling of a
patent number.160

154

Id. at 1683. The Court argues that the description of possible remedies for
an overbroad use code destroys “whatever remains of Novo’s argument.” Id. at
1684.
155
Id. at 1678. “According to the statute, a successful claimant may obtain an
order requiring the brand to ‘correct or delete’ its patent information.” Id. See also
21 U.S.C. § 355 (j)(5)(C)(ii)(I) (2012).
156
Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1684. Usually a brand
manufacturer will choose to delete a listing from the Orange Book entirely when it
holds no relevant patent, and will correct the information located in the listing
when the brand manufacturer has incorrectly described the patent’s scope. Id.
157
Id. at 1685.
158
Id. The Court does not take this argument very seriously and believes that
Novo “considerably understates the matter.” Id.
159
Id. Novo conceded to the Court that brand companies have strong
incentives to ensure that correct and accurate information is published in the
Orange Book (they also have major incentives to immediately correct any false or
incorrect information as soon as possible) because this information alerts both the
FDA and other companies that their drug patent is valid. Id. In other words,
publishing correct information in the Orange Book protects brand name
manufacturers from infringement by generic brand manufacturers. Furthermore,
the Court believes that generic manufacturers would have absolutely no incentive
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Furthermore, Novo has not even formulated a situation where the
counterclaim provision would be used to correct inaccurate patent
dates.161 Under Novo’s interpretation of the counterclaim, its use is
only appropriate if a listed patent “does not claim the drug or an
approved method of using it.”162 On the one hand, if a brand
manufacturer mistakenly lists the expiration date of an otherwise
valid patent (meaning it claims the drug or an approved use) as 2020
instead of 2015, the generic manufacturer would be barred from
bringing the counterclaim altogether (under Novo’s interpretation).163
On the other hand, if the brand manufacturer mistakenly published a
2015 expiration date when in reality the patent has already expired,
then the generic company could make use of the counterclaim
provision.164 However, in the latter situation, the correct remedy
would be a delisting of the patent instead of a correction of the
brand’s listing.165 Clearly, the counterclaim was created in order to
correct and delist inaccurate use codes, and not only numbers and
expiration dates under subsection (b) and (c) of 21 U.S.C. § 355.166

to bring a counterclaim against a brand name manufacturer merely to correct a
mislabeled patent. Id.
160
Id. See, e.g., TRW Inc. v. Andrews, 534 U.S. 19, 31 (2001) (refusing to
adopt an interpretation of a statute that would render a piece of it “insignificant, if
not wholly superfluous”). If Novo’s interpretation of how the counterclaim
provision works were true, the counterclaim would be almost entirely pointless.
The Court points out that it would have been, “in the most literal sense, to make a
federal case out of nothing.” Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at
1685.
161
Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1685.
162
Id.
163
Id. In the above hypothetical, “the counterclaim would be useless: It
authorizes a remedy only ‘on the ground that’ the listed patent does not claim the
drug or an approved method of using it—and notwithstanding the wrong expiration
date, this patent does so.” Id.
164
Id.
165
Essentially, “Novo's reading of ‘patent information,’ like its reading of ‘not
an,’ effectively deletes the term ‘correct’ from the statute.” Id.
166
Id.
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4. No Evidence Points to Congress Rejecting S. 812 Because It
Required Brands to Submit Patent Information Beyond a
Number and Expiration Date.
Novo argues that the Court’s interpretation of 21 U.S.C. § 355
basically revives parts of the Greater Access to Affordable
Pharmaceuticals Act of 2002, which was expressly rejected by the
United States Congress.167 The bill would have required brand name
companies to file specific information for method-of-use patents,
such as a description of “the approved use covered by the patent
claim.”168 Moreover, S. 812 would have provided generic brand
companies with their own form of civil action to compel brand name
companies to “delete” or “correct” inaccurate information filed with
the FDA.169 Novo argues that S. 812 would have allowed generic
brand companies to challenge overbroad patent descriptions, and thus
the Court “cannot read the statute Congress eventually enacted as
doing so.”170 The Court wholeheartedly disagrees with Novo’s
argument and sees no reason to assume that the reason Congress did
not pass S. 812 was because it required brand name companies to
submit a description of the approved uses claimed by the patent.171
S. 812 had several titles and provisions, any of which could have
been viewed unfavorably by Congress and been the reason for why
the House of Representatives took no action on the bill.172 S. 812

167

Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1685. S. 812 was able to
successfully pass through the United States Senate, however the House of
Representatives never voted on the bill, thus preventing it from being enacted into
Law. Id. at 1686.
168
Id. at 1686 (citing S. 812, 107th Cong., 2d Sess., § 103(a)(1), p. 7
(engrossed bill)).
169
Id.
170
Id.
171
Id. The Court believes, just like any layperson would, that “a bill can be
proposed for any number of reasons, and it can be rejected for just as many others.”
Id. at 1686 (citing Solid Waste Agency of N. Cook Cnty. v. Army Corps of Eng’rs,
531 U.S. 159, 170 (2001)). Novo attempts to argue that S. 812 was rejected by
Congress for one specific reason, however there were several aspects of S. 812 that
were unappealing and thus altered.
172
See generally S. 812, 107th Cong. § 804(b) (2002). One of the biggest
issues in S. 812 was Title II § 804 (b), which said, “[t]he Commissioner of
Customs, shall promulgate regulations permitting pharmacists and wholesalers to
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also received public criticism from several politicians because it
called for an independent cause of action, which was a more lengthy
legal action than the counterclaim provision that Congress ultimately
adopted.173 Moreover, Novo completely ignored a major reason as to
why the bill was redrafted.174 In between the demise of S. 812 and
the counterclaim’s enactment, “the FDA issued a rule requiring
brands to supply material concerning method-of-use patents,
including use codes.”175 According to the Court, the drafters of the
counterclaim provision were completely aware of the FDA ruling and
did not want to “duplicate its list of mandated filings.”176 Ergo, the
drafting history of the counterclaim does not support Novo’s ultimate
conclusion of Congress rejecting S. 812 because it required brands to
submit patent information beyond a patent number and expiration
date.177
5. Congress Did Not Establish the Counterclaim Merely to
Solve the Problem Raised by the Federal Circuit’s Decision in
Mylan.
Novo made one last attempt at an argument and stated that
“Congress established the counterclaim only to solve the problem
raised by the Federal Circuit’s decision in Mylan— the impossibility
of deleting an improperly listed patent from the Orange Book.”178 As
discussed earlier, Mylan involved a situation where a generic drug
import prescription drugs from Canada into the United States.” S. 812, 107th
Cong. § 804(b) (2002). Title II was highly controversial and likely would have
resulted in numerous lawsuits between U.S. and Canadian pharmaceutical
companies. Id.
173
E.g. Senator Gregg in discussing the challenges of passing S. 812 stated,
“the most significant issue is the fact that [S. 812] creates a new cause of action.”
148 CONG. REC. 15424 (2002) (remarks of Sen. Gregg). Basically, “the creation of
an independent cause of action [was] stronger medicine than the counterclaim
Congress ultimately adopted.” Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at
1686.
174
Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1686.
175
Id.
176
Id.
177
Id. The Court believes that “if anything, the statute's evolution indicates
that Congress determined to enforce the FDA's new listing provisions, including its
use–code requirement, through the new counterclaim.” Id.
178
Id.

Spring 2013

Brand Name or Generic?

371

manufacturer alleged that a brand name drug manufacturer submitted
a patent that neither claimed the drug, or any of its approved uses;
Mylan requested the patent be delisted.179 However, the court in
Mylan found that delisting the patent was not a remedy available to
Mylan180 under then current patent laws or the “Hatch–Waxman
Amendments to the Federal Food, Drug, and Cosmetic Act (FFDCA)
and to Title 35 of the United States Code.”181 Novo wanted the Court
to strictly construe the counterclaim provision to only help generic
drug manufacturers in Mylan’s exact situation.182 The Court once
again disagrees with Novo.183
Instead, the Court believes the decision in Mylan alerted
Congress to a major problem, which was that “generic companies
generally had no avenue to challenge the accuracy of brands’ patent
listings, and that the FDA therefore could not approve proper
applications to bring inexpensive drugs to market.”184 The Court
finds proof of this in the statute and its context, which demonstrate
that the counterclaim provision is available to generic companies
when brand companies publish patents with no basis, as well as
overbroad patents.185
Moreover, whether a brand name
179

See generally Mylan Pharm., Inc., v. Thompson, 268 F.3d 1323 (Fed. Cir.

2001).
“The Federal Circuit held that no such action was available, even assuming
the allegation was true. Because several legislators saw Mylan as ‘exemplifying
brands' ‘perceived abuse’ of the FDA's patent listing practices.” Caraco Pharm.
Laboratories, Ltd., 132 S. Ct. at 1686–87.
181
Mylan Pharm., Inc., 268 F.3d at 1325. See also supra note 58.
182
Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1687.
183
The Court does not draw any conclusions on whether the Mylan decision
incentivized legislators to create a counterclaim or not. Id. Instead they
emphasized the publishing of a study conducted by the FTC that deeply criticized
brand name pharmaceutical companies, and illustrated how brand manufacturers
would submit overbroad patents for publication to the FDA, thus preventing
generic drug companies from bringing their version of the drug to market. Id.
184
Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1687. The Court lamented
how “the statute's text and context demonstrate that the counterclaim is available
not only (as in Mylan) when the patent listing is baseless, but also (as here) when it
is overbroad.” Id. The opinion also goes on to say how “Congress's decision to
allow a counterclaimant to seek ‘correction’ of patent information explodes Novo's
theory, because the remedy for a Mylan–type impropriety is complete delisting.”
Id.
185
Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1687.
180
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pharmaceutical company publishes an overbroad patent or whether it
publishes a patent that covers absolutely no approved use, the bottom
line is that the company is “submit[ing] misleading information to the
FDA.”186 Essentially, the brand name manufacturer takes advantage
of the fact that the FDA does not have the manpower or necessary
qualified individuals to police incorrect and misleading
pharmaceutical drug patents.187 This prevents or severely delays
generic drugs that should otherwise go to market. Caraco’s situation
was extremely serious, as Novo wanted to prevent Caraco from
selling repaglinide for unpatented uses until 2018.188
The Court considers Caraco to be in even more need of the
counterclaim provision than Mylan, for several reasons. In Mylan,
the brand company listed a patent that claimed no approved use of
the drug.189 When a brand company does this, the generic company
has an alternative to the counterclaim provision, which is to make a
paragraph IV certification maintaining that the published patent “is
invalid or will not be infringed [on] by the generic drug.”190 If the
brand manufacturer decides to sue the generic company, the generic
company can argue that their drug will not infringe the patent.191 The
use of the counterclaim by the generic manufacturer against the brand
manufacturer may result in a quicker delisting of the patent, however,
“even without it the [generic manufacturer] can eventually get a
judgment of non-infringement enabling the FDA to approve its
ANDA.”192
In Caraco’s situation, where a brand company
purposefully files an overbroad use code description with the FDA,
the generic manufacturer is unable to use a paragraph IV certification
because it would require the generic manufacturer to propose
labeling identical to the brand name drug; furthermore, it cannot
186

Id.
Id. When brand name pharmaceutical companies submit incorrect patent
information, their actions “delay or block approval of a generic drug that infringes
no patent – and that under the statute should go to market.” Id. This is “the danger
Caraco faces here, as much as it was the threat in Mylan: Novo seeks to preclude
Caraco from selling repaglinide for unpatented uses until 2018, when Novo's patent
on a different use expires.” Id.
188
Id.
189
Mylan Pharm., Inc. v. Thompson, 268 F.3d 1323 (Fed. Cir. 2001).
190
See 21 U.S.C. § 355(j)(2)(A)(vii)(IV) (2012).
191
Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1687.
192
Id.
187
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carve out any uses.193 The proposed label will “infringe because it
will include the use(s) on which the brand does have a patent.”194
Thus, in Caraco’s situation, “a paragraph IV suit cannot lead to a
judgment enabling FDA approval.”195 The counterclaim provides the
only way for Caraco (or a generic drug manufacturer in a similar
situation) to bring its drug to market for “non-infringing uses.”196
Novo’s view would eliminate the counterclaim, thus preventing it
from being used where it is most helpful to generic drug
manufacturers.197 Thus, the Supreme Court in a 9-0 opinion ruled in
favor of Caraco.
B. Justice Sotomayor’s Concurring Opinion
Justice Sotomayor concurs with the Court’s interpretation of the
counterclaim in section 355198 and agrees that its reading of the
statute is the most sensible “in light of the existing regulatory
scheme.”199 However, she writes separately to make several
additional observations.200
Sotomayor strongly believes that the counterclaim in section 355
can only “lessen the difficulties created by an overly broad use code;
it cannot fix them.”201 Section 355 was specifically designed to
increase the production and approval time of generic drugs by the
FDA, so that American citizens have the option of purchasing a more

Id. “A paragraph IV certification (unlike a section viii statement) requires
the generic company to propose labeling identical to the brand's; it cannot carve out
any uses.” Id. See supra note 50.
194
Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1687.
195
Id.
196
Id. at 1687–88.
197
Id. at 1688.
198
Id. See also 21 U.S.C. § 355(j)(5)(C)(ii)(I) (2012). Justice Sotomayor
agrees with the Court’s interpretation of the counterclaim in section 355 “to permit
generic manufacturers to force brand manufacturers to ‘correct inaccurate use
code.’” Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1688 (Sotomayor, J.,
concurring). She too finds “the counterclaim not ‘free of ambiguity.’” Id.
199
Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1688 (Sotomayor, J.,
concurring).
200
Id. (Sotomayor, J., concurring).
201
Id. (Sotomayor, J., concurring).
193
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affordable version of their pharmaceutical drug.202 The generic drug
manufacturer must submit an ANDA with a section viii statement to
the FDA.203 Once the FDA receives the ANDA and section viii
statement, it can approve the application without further delay, as
long as the use code is not overly broad.204 When an overly broad
use code is submitted to the FDA, the process becomes much more
complicated.205 Sotomayor correctly points out that the Court’s
decision now permits generic drug manufacturers to bring a
counterclaim against the brand name manufacturer, once the brand
name manufacturer sues the generic company for patent
infringement.206 If the generic company successfully litigates the

“The statutory scheme is designed to speed the introduction of low–cost
generic drugs to market.” Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1688
(Sotomayor, J., concurring) (citing Eli Lilly & Co. v. Medtronic, Inc., 496 U.S.
661, 676 (1990)).
203
Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1688 (Sotomayor, J.,
concurring). Along with the ANDA and section viii statement, the generic drug
company must submit a “proposed label that ‘carves out’ from the brand
manufacturer’s label any patented method of use.” Id. See supra note 50
(providing an explanation of “carving out”).
204
Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1688 (Sotomayor, J.,
concurring).
205
Id. (Sotomayor, J., concurring). The reason an overbroad use code
complicates things is very straightforward. The Federal Drug Administration
“relies on use codes in determining whether to approve an ANDA, but it refuses to
evaluate the [use code’s accuracy].” Id. (Sotomayor, J., concurring). “If the use
code overlaps with the generic manufacturer's proposed carve–out label (i.e., the
use code is overly broad), FDA will not approve an ANDA with a section viii
statement.” Id. (Sotomayor, J., concurring).
206
Id. at 1688 (Sotomayor, J., concurring).
202

After today's opinion, the generic manufacturer can respond
to this situation by taking the following steps: submit an ANDA
with a paragraph IV certification (which requires a proposed
label materially identical to the brand manufacturer's label), wait
for the brand manufacturer to institute suit, file a counterclaim,
and then litigate the counterclaim. [If the generic company is]
successful in securing the correction of the use code, [it can]
return to the start of the process and do what it always wanted to
do—file an ANDA with a section viii statement and a carve–out
label.
Id. (Sotomayor, J., concurring).
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counterclaim and compels the brand name company to either correct
or delete the overbroad use code, they can return to the beginning of
the process and submit their ANDA, section viii statement, and
carve-out label.207
Justice Sotomayor finds two major problems with the
counterclaim provision. First, it results in major delays and
expenses, which the statutory scheme did not foresee; second, there is
absolutely no guarantee that the process will work.208 The Court
knows what will happen if a brand company initiates paragraph IV
litigation over an overbroad use code,209 but it is unclear “if the brand
name company does not file.”210 Justice Sotomayor strongly believes
the counterclaim “cannot restore the smooth working of a statutory
scheme thrown off kilter by an overly broad use code.”211 At the
very best, the statutory scheme allows the generic drug manufacturer
to file an ANDA with a section viii statement, “but only after
expensive and time-consuming litigation.”212 Justice Sotomayor
laments that either the FDA or Congress needs to take action and
address the problem.213

207

Id. (Sotomayor, J., concurring).
Id. at 1688–89 (Sotomayor, J., concurring).
209
Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1689 (Sotomayor, J.,
concurring). The outcome of paragraph IV litigation over an overbroad use code
“will be the correction of the use code through the assertion of a counterclaim—an
outcome that is desirable, to be sure, for the generic manufacturer, but perhaps less
so for the brand manufacturer.” Id. at 1689 (Sotomayor, J., concurring).
210
Id. The FDA “may approve the generic manufacturer's application,
‘without prejudice to infringement claims the patent owner might assert when the
ANDA applicant produces or markets the generic drug.’” Id. (Sotomayor, J.,
concurring). However, the generic brand manufacturer having been forced to
continue with a paragraph IV certification, “will have secured approval to market a
drug with a label materially identical to the brand manufacturer's.” Id. (Sotomayor,
J., concurring). The Solicitor General's Office informed the Court at oral
arguments that “it would be inducement of infringement to sell a product with
labeling that suggests that the product be used for a patented method of use.” Id.
(Sotomayor, J., concurring). Basically, if a generic drug manufacturer filed a
paragraph IV certification, the proposed labeling would be infringing, so long as
the brand name manufacturer’s patent covered an approved method of using the
approved drug. Id. (Sotomayor, J., concurring).
211
Id. (Sotomayor, J., concurring).
212
Id. (Sotomayor, J., concurring).
213
Id. (Sotomayor, J., concurring).
208
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Sotomayor goes on to say that the regulatory scheme is dependent
on the accuracy of the use codes, and that the FDA’s “guidance as to
what is required of brand manufacturers in use codes [is] remarkably
opaque.”214 Some of the confusion is due to the FDA’s failure to
describe what is required of brand name manufacturers; Novo
experienced difficulties and confusion in filing their use code
description with FDA.215 However, the Court explained in its

214

Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1689 (Sotomayor, J.,
concurring). “The relevant regulation states simply that a brand manufacturer must
provide ‘[t]he description of the patented method of use as required for
publication.’”
Id. (Sotomayor, J., concurring) (citing 21 C.F.R. §
314.53(c)(2)(ii)(P)(3)). The new drug application forms contain information with
additional details explaining how:
Each approved use claimed by the patent should be separately
identified . . . and contain adequate information to assist . . .
applicants in determining whether a listed method of use patent
claims a use for which the . . . applicant is not seeking approval.
Id. at 1689 (Sotomayor, J., concurring).
However, the form also mentions that brand name drug companies may “use no
more than 240 total characters including spaces.” Id. (Sotomayor, J., concurring).
Elsewhere, the “FDA acknowledges ‘that in some cases 240 characters may not
fully describe the use as claimed in the patent.’” Id. (Sotomayor, J., concurring)
(citing 68 Fed. Reg. 36683 (2003)). This indicates that use codes “are not meant to
substitute for the applicant's review of the patent.” Caraco Pharm. Laboratories,
Ltd., 132 S. Ct. at 1689 (Sotomayor, J., concurring).
215
Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1689 (Sotomayor, J.,
concurring). Sotomayor points out that when Novo filed its initial NDA, it
“submitted a use code for the § 358 patent that was not ‘overly broad’: It described
narrowly the single patented method of use.” Id. (Sotomayor, J., concurring).
Several years later the FDA required Novo to amend its label to “separate all
indications with the following sentence: ‘Prandin is indicated as an adjunct to diet
and exercise to improve glycemic control in adults with type [two] diabetes
mellitus.’” Id. at 1690 (Sotomayor, J., concurring). Novo proceeded to amend its
use code to comply with the FDA requirements, and explained that the amendment
corresponded with the requests of the FDA. Novo believed its newly amended use
code “[complied] with FDA regulations, . . . on the ground it pressed before [the
Court]: that the regulations permit a brand manufacturer to submit for publication
in the Orange Book a description of either the patented method of use or the
indication (which refers to ‘what a drug does’).” Id. at 1690 (Sotomayor, J.,
concurring).
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majority opinion why Novo was mistaken, yet Sotomayor believes
“[Novo] can hardly be faulted for so thinking.”216
Justice Sotomayor concludes by mentioning that prior to the
enactment of the counterclaim provision, “Congress considered a bill
that required brand manufacturers to submit a description of the
approved use covered by the patent claim.”217 The legislation
allowed a generic manufacturer to bring an independent civil action
and force a brand name manufacturer to correct or remove an
overbroad use code.218 S. 812 received all kinds of criticism and was
eventually rejected by Congress. Politicians stated that the bill would
encourage excessive litigation.219 Sotomayor believes “[a]bsent
greater clarity from FDA concerning what is required of brand
manufacturers in use codes, Congress’s fears of undue litigation may
be realized.”220
VI. POSSIBLE SOLUTIONS
Justice Sotomayor’s concurring opinion indicates that the Court’s
decision in Caraco has not even come close to fixing all of the
problems associated with the counterclaim provision and that both
Congress and the FDA must take further steps to achieve a complete
resolution.221 As it stands today, the FDA will not review the patents
submitted to it for compliance with the Hatch-Waxman Amendments

216

Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1690 (Sotomayor, J.,
concurring). “The regulations also require submission of “a description of each
approved method of use or indication.”
Id. (citing 21 C.F.R. §
314.53(c)(2)(ii)(P)(1)). Also, the form on which the brand name drug company
submits its use code “requires information on the indication or method of use for
the Orange Book ‘Use Code’ description.” Id. (Sotomayor, J., concurring).
Sotomayor states that “those sources at the least suggest (as Novo thought) that a
method of use here is distinct from an indication and that either suffices as a use
code.” Id. (Sotomayor, J., concurring).
217
Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1690 (Sotomayor, J.,
concurring).
218
Id. (Sotomayor, J., concurring).
219
Id. (Sotomayor, J., concurring). See supra notes 171–173.
220
Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1690 (Sotomayor, J.,
concurring).
221
Id.
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that were passed in 1984.222 The agency adopts a “hands-off” policy
when it comes to patents and refuses to conduct any type of due
diligence to safeguard from overly broad or inaccurate method-of use
codes being submitted for publication in the Orange Book. 223 The
FDA’s current hands-off position is the reason why certiorari was
granted for the Caraco case, because the FDA’s “policy incentivizes
[brand manufacturers] to draft use code narratives that are
inappropriately broad to force applicants to file Paragraph IV
certifications.”224
A. Increase the Level of Review
Prior to the Court’s decision in Caraco, two senior attorneys (Mr.
Malkin and Mr. Wasson) published an article making several
recommendations for how the FDA should proceed.
Their
suggestions were criticized, yet they are now more relevant than
ever.225 In essence, they suggest that the FDA “internally review
patents beyond the ministerial requirements of its current regulations
to more efficiently administer the balance between an NDA-holder
and generic applicant.”226 First, and most importantly, the FDA
should review patents submitted for publication in the Orange Book
for accuracy and “should proactively refuse to list patents that do not
meet FDA’s listing criteria.”227 Second, “in the event that an
applicant submits carved-out labeling, confirm that the listed methodof-use patent does not claim a use for which the application is

The FDA has stated: “because FDA has no expertise in the field of patents,
the agency has no basis for determining whether a use patent covers the use sought
by the generic applicant.” Abbreviated New Drug Application Regulations;
Proposed Rule, 54 Fed. Reg. 28872, 28909 (July 10, 1989). See also supra note
52, where the FDA explains how its administration lacks both the expertise and
authority to review patent claims.
223
Id.
224
Brian J. Malkin & Andrew S. Wasson, Should FDA Undertake More Than
A Ministerial Role With Respect to Patent Information?, 1 THE FOOD AND DRUG
LAW INST. FOOD AND DRUG POL’Y FORUM 1, 1 (2011) [hereinafter FDA:
Ministerial Role].
225
See generally Malkin & Wasson, supra note 224.
226
Id. at 5. Malkin and Wasson advocate for various limits on the internal
review. Id.
227
Id.
222
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submitted.”228 The FDA should be allowed to retain use code
narratives for informational use, so that they might refer back to them
or compare them to future submissions.229
A major benefit of the above proposal is that the FDA will be
able to act as a “neutral arbiter” and hold NDA applicants
accountable for inaccurate information they submit for publication in
the Orange Book.230 The FDA would be able to unilaterally delist
patents that have over broad use codes.231 Giving the FDA the ability
to delist patents takes this power out of the hands of brand
manufacturers (who often times have an interest in publishing
overbroad use codes) and places it in the hands of a “neutral
arbiter.”232 Brand name manufacturers would have an incentive not
to submit overbroad or inaccurate method-of-use patents for fear that
they would be rejected by the FDA. Malkin and Wasson point out
how this exact reasoning applies to the “FDA’s role in determining
whether an applicant can carve-out . . . a product.”233 Basically,
instead of the brand manufacturer having the sole power to decide the
scope of the patent, which could potentially prevent a non-infringing
generic drug manufacturer from achieving the approval of their
“505(b)(2) ANDA, the FDA would ‘assume the decision making
role.’”234 Most likely, “the number of questionable patent listings
and use code narratives would decrease . . . because [brand
manufacturers] would be less likely to submit inappropriate patent
listings or use codes’ narratives knowing that this information would
face a substantive FDA review.”235 Brand name manufacturers
would be dissuaded from submitting inaccurate use codes to the FDA
for publishing if there was a possibility that the patent could be
rejected because its method-of-use statement is overbroad or wholly
inaccurate.

228

Id.
Id.
230
FDA: Ministerial Role, supra note 224, at 6.
231
Id.
232
Id. Placing this type of power in the hands of the FDA would provide some
“balance between competing interests.” Id.
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B. Hire Patent Attorneys With Backgrounds in
Pharmaceuticals or Medicine
The FDA has made it completely clear that it does not “have the
expertise to review patent information,” which is why the FDA needs
to hire patent attorneys with a background in pharmaceuticals or
medicine.236 Having a small staff of patent attorneys with medical or
scientific backgrounds “would confer other benefits on FDA.”237
The attorneys could assist with legal interpretations of “other
complicated scientific issues that have regulatory and legal
implications, such as the . . . biosimilars legislation or difficult
scientific/regulatory
issues
like
some
bioequivalence
238
determinations.”
Furthermore, FDA patent attorneys could “work
with the Patent Office on the patent term restoration program, which
was also included in the Hatch-Waxman Act, allowing the FDA to
engage in more robust and efficient discussions with the Patent
Office on eligibility and regulatory review period determinations.”239
Having attorneys on staff who are experienced in patent law and have
a thorough understanding of the scientific and medical realms would
allow the FDA to react more quickly to unexpected and complicated
patent issues that arise.240
The FDA’s legal department could begin small with four or five
patent attorneys and make adjustments in the future as needed. The
median salary for an attorney employed by the United States
Government is $87,008.241 Assuming the FDA is able to employ six
patent attorneys and pay each of them a median salary, they would

Id. Malkin and Wasson “concede that the analysis of determining whether
a method–of–use patent claims a use for which the generic application is submitted
requires a more refined skill–set than a patent listing determination . . . this analysis
would not be beyond the skills of the competent patent attorneys hired by the
FDA.” Id.
237
Id. at 7.
238
Id.
239
Id.
240
FDA: Ministerial Role, supra note 224, at 7.
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See Pay Scale: Attorney, Government Salary (Feb. 6, 2013), available at
http://www.payscale.com/research/US/Job=Attorney,_Government/Salary.
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need to come up with an additional $522,048 per year ($43,504 per
month) in order to fund the legal department.242
VII.

FDA COUNTERARGUMENTS

The FDA might make several counterarguments against adopting
the above suggestions; however, senior attorneys Malkin and
Wasson, as well as Justice Sotomayor, provide several compelling
counterarguments to the FDA taking a “hands-off” approach.
A. The Scope and Validity of Patents Belong With the Courts
The FDA has argued that expanding its role will be extensive and
that it will not be able to accomplish the task due to its lack of
experience.243 However, Malkin and Wasson highlight how the FDA
has some experience in determining difficult and complex issues,
“for example, responding to FTC’s call to clarify types of patents
appropriately listed in the Orange Book.”244 The FDA is already
familiar with the “hallmarks and characteristics” of various
pharmaceutical patents, and it is not unreasonable to ask the FDA to
perform a more thorough job in determining whether a patent that has
been submitted for publication meets the FDA’s criteria.245 The FDA
has mentioned that it would rather focus on ensuring that drugs are
safe and effective for the American public and let drug manufacturers
sort out their differences that arise from paragraph IV.246 However,
if the FDA would take a more hands on approach and review NDA
applications for accuracy, it may very well cut down on litigation and
solve part of the problem.
Furthermore, the FDA’s previous contention that “disputes
relating to the scope and validity of patents . . . belong with the

242
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FDA: Ministerial Role, supra note 224, at 7.
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Id. In this particular situation the “FDA made a fine–grained determination
that patents claiming active ingredients, formulations, methods of use, products–
by–process and polymorphs could be listed in the Orange Book, while patents
claiming metabolites, packaging, intermediates and processing could not be listed
in the Orange Book.” Id.
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courts, given the court’s experience, expertise and authority in
complex patent matters,” may be dead in the water, given Justice
Sotomayor’s concurring opinion urging Congress and the FDA to
take further action.247 Prior to the Supreme Court’s decision in
Caraco, the District Courts and the Federal Circuits, “ratified FDA’s
position,” that they “lack expertise to weigh in on patent issues.”248
However, in Caraco, Sotomayor specifically criticizes the FDA’s
guidance, referring to it as “remarkably opaque;” she also mentions
how the FDA’s approach towards reviewing use codes was part of
the reason why Caraco went all the way up to the Supreme Court.249
Hopefully the FDA will recognize the Supreme Court’s criticisms
and take to heart what the Court and Malkin and Wasson have
suggested.
B. The FDA’s Patent Decisions Would Lead to
Increased Litigation Against the Agency
Finally, the FDA may attempt to argue, “FDA’s patent decisions
would inevitably lead to increased litigation against the agency.”250
Malkin and Wasson highlight that while this may be true in the short
run, “avoiding litigation should not be a guiding principle for sound
regulatory policy.”251 Simply put, the FDA cannot refrain from
making substantive decisions just because one of the decisions could
potentially end up in litigation.252 Not to mention, if the FDA hires
several patent attorneys, they would be able to effectively handle any
lawsuit brought against the agency. The FDA might also argue that
“there is no guarantee that a more robust patent review procedure
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FDA: Ministerial Role, supra note 224, at 7. “[I]t is . . . true that these
courts have found FDA’s position to be reasonable, . . . these courts do not appear
to mandate that the FDA maintain this policy, especially in light of the
circumstances where it is not working or it causes a delay in the availability of
generic products.” Id.
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See supra notes 209–10.
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FDA: Ministerial Role, supra note 224, at 7.
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Id. The FDA is in the “business of making substantive decisions: each
could potentially end up in litigation.” Id. The FDA “would be paralyzed if it did
not act due to fear of litigation.” Id.
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would lead to facilitated generic entry.”253 However, it appears that a
more substantive and robust review procedure would have
“facilitated generic entry” in the case of Caraco.254 If a more
proactive FDA would have made the decision that the “listed
method-of-use patent did not claim a use for which the generic
applicant submitted the application, the generic applicant would have
been allowed to maintain its statement under subsection viii and
would not have been subject to . . . unnecessary litigation.”255
VIII.

RECENT FDA AND CONGRESSIONAL DEVELOPMENTS

In the past, the FDA has criticized the idea of taking a “more
hands on approach” when it comes to increasing its substantive level
of review of drug patents. Currently, “A Generic Drug User Fee Act
is on the way, to enable the U.S. Food and Drug Administration to
levy a user fee of around $100,000 on each generic drug application
filed for approval.”256 As of now, there is no fee for filing an ANDA
with the FDA.257 According to estimates made by Infrastructure
Development Finance Corporation (IDFC Securities),258 once
Congress passes the act, it will generate an “additional $229 million
per annum from generic [drug manufacturers].”259 Of the $229
million, “30% is likely to come from the processing of ANDA’s and
drug master files [license to make bulk drugs], and the rest from its
inspection of various facilities.”260 Other sources have mentioned
253
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that these estimates could vary, depending on “the product’s market
size.”261 The proposed legislation is “expected to give the FDA the
additional resources required to improve the review of drug
[patents].”262 The additional revenue raised from the passage of this
act should give the FDA breathing room to hire additional patent
attorneys who will thoroughly review and analyze complex patent
issues and situations. Furthermore, the FDA’s legal department will
be able to handle any lawsuit filed against the agency that relates to
the FDA’s patent decisions. The additional revenue should also
make the FDA’s patent review process more effective, as the agency
will be able to hire additional members that will be tasked with
reviewing drug applications to make sure they comply with the
statutory requirements.
The recent development of a “Generic Drug User Fee Act” is
extremely significant, and it is in everyone’s interest to get the
legislation passed as soon as possible, as a “significant number of
Indian companies are targeting various generic launches in the U.S.,
in the wake of expiring patents.”263 Indian drug companies play a
major role in the U.S. market, and make up around ten percent of the
U.S. pharmaceutical market.264 It is extremely important for
Congress to quickly pass the Generic Drug User Fee Act, so that the
FDA does not miss out on the potential for major increases in its
revenue from the filing of ANDA applications on behalf of Indian
pharmaceutical companies.265
IX. CONCLUSION
The United States Supreme Court decision in Caraco was a
landmark decision in the pharmaceutical industry, especially for
generic drug manufacturers like Caraco. The unanimous decision by
the Court made it clear that generic manufacturers may bring a
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counterclaim to compel brand name manufacturers to either correct
or delete overbroad method-of-use codes. The Court’s ruling closed
a longstanding loophole that has been exploited by brand name
manufacturers since the late 1990’s. However, Justice Sotomayor
made it readily apparent that the Court’s decision neither addressed
all questions nor fixed all the problems with the counterclaim
provision. The FDA to this day takes a “hands-off” approach when it
comes to the substantive review of method-of-use codes submitted by
brand name drug manufacturers for publication in the Orange Book.
In order to solve many of the lingering issues, the FDA must rise
to the occasion and raise its substantive level of review, police patent
codes for accuracy, and proactively refuse to list overbroad methodof-use patents that do not comply with FDA requirements.
Furthermore, the FDA should create a separate legal department and
hire several patent attorneys with backgrounds in science to grapple
with the more complicated patent issues that arise. The FDA can no
longer argue that U.S. courts support its “hands-off” level of review
approach, as Sotomayor criticizes their current approach and urges
the FDA to make major changes. After the Caraco decision, it
appears that both the FDA and Congress are working together to
provide for major changes regarding the FDA’s review of drug
patents. Congress will likely pass a “Generic Drug User Fee Act,”
which will allow the FDA to charge generic manufacturers up to
$100,000 per ANDA application. It is estimated that the new act will
generate upwards of $200 million dollars per year in revenue for the
FDA, which should cover its costs for patent attorneys, and greatly
increase the ANDA approval rate. It seems that both Congress and
the FDA have heard the cries from the Supreme Court, especially
those of Justice Sotomayor, and are working to develop a solution as
quickly as possible.

